ICMR: Covaxin Effective Against Delta Plus Variant

Delta variant is identified as the leading cause of breakthrough infections globally among vaccinated individuals. The Delta variant has also mutated to Delta AY.1, AY.2, and AY.3 variants. Of these, Delta AY.1 variant (also known as Delta Plus) was first detected in India in April 2021 and subsequently in twenty other countries.

A new study by the Indian Council of Medical Research (ICMR) revealed that covaxin is effective against this Delta Plus (AY.1) variant of the SARS-CoV2 virus. Despite a slight reduction in the neutralization of antibody titers, Covaxin is still effective against Delta, AY.1 (Delta Plus), and B.1.617.3 variants, the study stated. Although the prevalence of the Delta plus variant is low in India (with only 70 cases of Delta Plus variant found in genome sequencing by INSACOG), there has been no information on the efficacy of currently available vaccines against the Delta AY.1 variant.

Researchers said that a minor reduction was observed in the neutralizing antibody titer in Covid- 19 recovered cases, fully vaccinated and post-immunized infected cases compared to Covid-19-naive vaccinated individuals. The study had evaluated the IgG antibody titer and neutralizing potential of sera of Covid-19-naive individual’s total doses of Covaxin vaccine, Covid-19-recovered cases with full dose vaccines, and breakthrough cases with post-immunization Covaxin vaccines against Delta, Delta AY.1 and B.1.617.3.

Although the sera of Covid recovered cases with vaccinations and breakthrough cases of infection showing a considerable reduction in the neutralization antibody titer, Covaxin could still neutralize Delta, AY.1, and B.1.617.3 variants.

Source: ICMR



All About COVID-19 For Your Patients

WhiteCoats Insights For Your Practice

Join Thousands of Doctors who Trust WhiteCoats as their Professional Success Partner

For more queries, Call +91-7406-485-000 or mail us at sales@whitecoats.com

Download our App